CAS 38821-49-7|Carbidopa monohydrate

Introduction：Basic information about CAS 38821-49-7|Carbidopa monohydrate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Carbidopa monohydrate BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Customs
7. Articles48
8. Synonyms

Common Name	Carbidopa monohydrate
CAS Number	38821-49-7	Molecular Weight	244.244
Density	1.42 g/cm3	Boiling Point	528.7ºC at 760 mmHg
Molecular Formula	C₁₀H₁₆N₂O₅	Melting Point	/
MSDS	ChineseUSA	Flash Point	273.5ºC
Symbol	GHS07	Signal Word	Warning

Names

Name	carbidopa
Synonym	More Synonyms

Carbidopa monohydrate BiologicalActivity

Description	Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth[1][2].
Related Catalog	Research Areas >>CancerSignaling Pathways >>Immunology/Inflammation >>Aryl Hydrocarbon ReceptorResearch Areas >>Neurological Disease
In Vitro	Carbidopa ((S)-(-)-Carbidopa) monohydrate exhibits activities similar to that described for other AhR ligands in BχPC3 and Capan-2 cells, namely the induction of CYP1A1 and CYP1A2, which are inhibited by AhR antagonists such as CH223191[1]. Carbidopa, a aromatic-L-amino acid decarboxylase inhibitor, is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Carbidopa is lethal (IC50=29 μM)[3].
In Vivo	Carbidopa monohydrate also induces nuclear uptake of the AhR, and in vivo studies show that carbidopa at a dose of 1 mg/mouse significantly inhibits tumor growth in athymic nude mice bearing BχPC3 cells as xenografts[1].
References	[1]. Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J. 2017;474(22):3763-3765. Published 2017 Nov 6. [2]. Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43(12):587-591. [3]. Gilbert JA, et al. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6(11):4365-4372.

Chemical & Physical Properties

Density	1.42 g/cm3
Boiling Point	528.7ºC at 760 mmHg
Molecular Formula	C₁₀H₁₆N₂O₅
Molecular Weight	244.244
Flash Point	273.5ºC
Exact Mass	244.105927
PSA	125.04000
LogP	0.97380
InChIKey	QTAOMKOIBXZKND-PPHPATTJSA-N
SMILES	CC(Cc1ccc(O)c(O)c1)(NN)C(=O)O.O

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MW5300000

CHEMICAL NAME :: Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate

CAS REGISTRY NUMBER :: 38821-49-7

LAST UPDATED :: 199707

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C10-H14-N2-O4.H2-O

MOLECULAR WEIGHT :: 244.28

WISWESSER LINE NOTATION :: ZMX1&VQ2R &QH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4810 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 352 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3428 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - other changes Skin and Appendages - hair

REFERENCE :: SKKNAJ Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. (Sankyo K.K. Sogo Kenkyusho, 1-2-58 Hiro-machi, Shinagawa-ku, Tokyo 140, Japan) No.15- 1963- Volume(issue)/page/year: 28,116,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1750 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 148 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 4955 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - ataxia Skin and Appendages - hair

REFERENCE :: SKKNAJ Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. (Sankyo K.K. Sogo Kenkyusho, 1-2-58 Hiro-machi, Shinagawa-ku, Tokyo 140, Japan) No.15- 1963- Volume(issue)/page/year: 28,116,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 519 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >600 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression Kidney, Ureter, Bladder - hematuria

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

Safety Information

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H319
Precautionary Statements	P305 + P351 + P338
RIDADR	NONH for all modes of transport
WGK Germany	3
HS Code	2932999099

Customs

HS Code	2928000090
Summary	2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%

Articles48

[(11)C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.

J. Cereb. Blood Flow Metab. 34(1) , 118-25, (2014)

The PET tracer [(11)C]5-hydroxytryptophan ([(11)C]5-HTP), which is converted to [(11)C]5-hydroxytryptamine ([(11)C]5-HT) by aromatic amino acid decarboxylase (AADC), is thought to measure 5-HT synthes...

Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.

Eur. J. Drug Metab. Pharmacokinet. 39(4) , 237-42, (2014)

The objective of this study was to investigate the pharmacokinetic characteristics of levodopa (L-dopa) from nasal powder formulations using highly water-soluble levodopa methyl ester hydrochloride (L...

Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

Cancer Res. 74(21) , 6205-15, (2014)

Cancers due to germline mutations in the BRCA1 gene tend to lack targets for approved chemoprevention agents. This study aimed at a targeted chemoprevention strategy for BRCA1-associated malignancies....

Synonyms

Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-, hydrate (1:1)

CARBIDOPA 1-HYDRATE,PHARMA

Carbidopa

(S)-Carbidopa

1-a-(3,4-Dihydroxybenzyl)-a-hydrazinopropionic Acid

L-a-Methyldopahydrazine

(aS)-a-Hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic Acid

CARBIDOPA MONOHYDRATE

(S)-(-)-CARBIDOPA MONOHYDRATE

a-Methyldopahydrazine

Lodosin

carbidopa [INN_en]

CARBIDOPA HYDRATE

CARBIDOPA(GMP CERTIFICATE)

(S)-(-)-Carbidopa

HMD

CARBIDOPA,USP

(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid hydrate (1:1)

(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid

S-(−)-Carbidopa

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-

CARBIDOPA 1-HYDRATE

benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-

(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (1:1)

MFCD00889211

benzenepropanoic acid, a-hydrazinyl-3,4-dihydroxy-a-methyl-, (aS)-

Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-

lodosyn

S-(-)-Carbidopa

(-)-L-a-Hydrazino-3,4-dihydroxy-a-methylhydrocinnamic Acid

(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid

Hydrazino-a-methyldopa

Recommended......